Skip to main content
Home
language-selector-globe Canada | en
Choose location
language-selector-globe Canada |
EnglishFrançais
  • Americas
  • Asia Pacific
  • Europe
  • International
  • Middle East & Africa
Argentina | es
Brazil | pt
Canada | en
Canada | fr
Central America | es
Colombia | es
Mexico | es
United States | en
Venezuela | es
Australia | en
Bangladesh | en
Hong Kong S.A.R. | zh
India | en
Indonesia | en
Japan | ja
Korea | ko
Mainland China | zh
Malaysia | en
Pakistan | en
Philippines | en
Singapore | en
Taiwan | zh
Austria | de
Belgium | fr
Belgium | nl
Bulgaria | bg
Czech Republic | cs
Czech Republic | en
Denmark | da
Estonia | et
Finland | fi
France | fr
Germany | de
Greece | el
Hungary | hu
Ireland | en
Italy | it
Latvia | lv
Lithuania | lt
Netherlands | nl
Norway | no
Poland | pl
Portugal | pt
Romania | ro
Russia | ru
Serbia | sr
Slovakia | sk
Spain | es
Sweden | sv
Switzerland | de
Switzerland | fr
United Kingdom | en
Global | en
Novartis Foundation | en
Sandoz | en
Egypt | en
Israel | he
South Africa | en
Turkey | tr
language-selector-globe Canada
Choose location
language-selector-globeCanada
EnglishFrançais
Americas Asia Pacific Europe International Middle East & Africa
Argentina | es
Australia | en
Austria | de
Bangladesh | en
Belgium | fr
Belgium | nl
Brazil | pt
Bulgaria | bg
Canada | en
Canada | fr
Central America | es
Colombia | es
Czech Republic | cs
Czech Republic | en
Denmark | da
Egypt | en
Estonia | et
Finland | fi
France | fr
Germany | de
Global | en
Greece | el
Hong Kong S.A.R. | zh
Hungary | hu
India | en
Indonesia | en
Ireland | en
Israel | he
Italy | it
Japan | ja
Korea | ko
Latvia | lv
Lithuania | lt
Mainland China | zh
Malaysia | en
Mexico | es
Netherlands | nl
Norway | no
Novartis Foundation | en
Pakistan | en
Philippines | en
Poland | pl
Portugal | pt
Romania | ro
Russia | ru
Sandoz | en
Serbia | sr
Singapore | en
Slovakia | sk
South Africa | en
Spain | es
Sweden | sv
Switzerland | de
Switzerland | fr
Taiwan | zh
Turkey | tr
United Kingdom | en
United States | en
Venezuela | es
    • About 
      • Novartis in Canada 
        • Novartis Biome in Canada 
      • Strategy 
      • Diversity and Inclusion 
      • People and Culture 
      • Products 
      • Stories 
      About Novartis Canada About
    • Patients and Caregivers 
      • The Novartis Commitment to Patients and Caregivers 
      • Adverse Event Reporting 
      • Grants and Donations 
      • Stories 
      Patients and Caregivers Patients and Caregivers
    • Healthcare Professionals 
      • HCP Portal 
      • Products 
      • Pipeline (EN) 
      • Adverse Event Reporting 
      • Novartis Clinical Trials 
      • Disclosure Of Payments To Healthcare Professionals 
      Healthcare Professionals Header Image Healthcare Professionals
    • ESG 
      • Ethical Behavior 
        • Code of Ethics 
        • SpeakUp 
      • Grants and Donations 
      • Corporate Responsibility 
        • AODA Compliant - EN (PDF 0.2 MB) 
        • AODA Compliant - FR (PDF 0.2 MB) 
        • AMA Compliant - EN (PDF 0.2 MB) 
        • AMA Compliant - FR (PDF 0.2 MB)  
        • Disclosure Of Payments To Healthcare Professionals 
        • Environmental Sustainability 
      ESG Header ESG
    • Careers 
      • Diversity & Inclusion 
      • People and Culture 
      • Career Search 
      • How We Work 
      • Well-being 
      • Stories 
      Careers Header Careers
    • Contact 
      • Email Us 
      • For Consumers 
      • General contact 
      • Canadian Locations 
    • News Archive | Novartis Canada 
    About Novartis Canada Home
Header
News

News

News and more from the frontiers of medicine

Previous Next

Media inquiry

For Journalists with a media inquiry, please contact us:


Novartis Pharmaceuticals Canada Inc.
Department of Communications
385 Bouchard Blvd.
Dorval, Quebec H9S 1A9

Phone: (514) 633-7873

Media Releases

Media Releases

Media releases are intended for journalists, investors, and shareholders.

Stories

Stories

Our research redefines the way we understand disease and develop medicines. Discover the people and stories that make it possible.

20 Nov 2023 08:06:00 AM.@NovartisNews

At #SABCS23 & #ASH23, we are presenting data from over 100 trials across its breast cancer and hematology portfolios, including significant data updates in breast cancer, PNH and CML. #NovartisNews https://t.co/m74FowX1AJ

Previous Next

Novartis Canada

Navigate Novartis
  • Patients & Caregivers
  • Healthcare Professionals
  • HCP Portal
  • ESG
  • Careers
  • Contact
Media Center
  • News Archive
  • Stories
Our Portfolio
  • Novartis Clinical Pipeline
  • Novartis Product Portfolio
Other Novartis Websites
  • Global site
Footer Bottom
© 2023 Novartis AG
  • Terms of Use
  • Privacy Policy
  • Web Accessibility
  • Cookie Settings
  • Site Map
Novartis Site Directory
This site is intended for an audience in Canada.